Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation. [electronic resource]
Producer: 20201026Description: 312-322 p. digitalISSN:- 1615-2573
- Adult
- Aged
- Aged, 80 and over
- Aspirin -- administration & dosage
- Clopidogrel -- administration & dosage
- Coronary Artery Disease -- blood
- Cytochrome P-450 CYP2C19 -- genetics
- Drug Resistance -- genetics
- Drug Substitution -- adverse effects
- Drug-Eluting Stents
- Dual Anti-Platelet Therapy
- Female
- Humans
- Japan
- Male
- Middle Aged
- Percutaneous Coronary Intervention -- adverse effects
- Pharmacogenomic Variants
- Platelet Aggregation -- drug effects
- Platelet Aggregation Inhibitors -- administration & dosage
- Polymorphism, Single Nucleotide
- Prasugrel Hydrochloride -- administration & dosage
- Purinergic P2Y Receptor Antagonists -- administration & dosage
- Risk Factors
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.